Dr Erik Bogsch is Head of the Biotechnology Unit at Richter Gedeon Plc. He holds a degree from the University of Cambridge and earned his PhD from the University of Warwick, where he also worked as a postdoctoral researcher. His academic research focused on protein transport processes in plant cells, and he has published several scientific papers in the field.

Between 1999 and 2011, Dr Bogsch held senior positions at Mars Inc. in the food industry, contributing to product development, quality assurance, manufacturing, and portfolio management across the UK, Hungary, and Germany.

He joined Richter Gedeon in 2012, initially overseeing the commissioning of the company’s biotechnology plant in Debrecen, and later leading its R&D department. Since 2020, he has headed the Biotechnology Business Unit, which is responsible for the development, production, and strategic direction of biotechnology-based medicines. Under his leadership, a unique pharmaceutical biotechnology hub was established, playing a pivotal role in shaping Hungary’s industrial biotechnology sector and raising it to international standards. Today, this hub remains a key player in the field. One of its flagship achievements is Richter’s biosimilar teriparatide product, which has become a global market leader and was awarded the Hungarian Innovation Grand Prize in 2020.

Dr Bogsch previously served as a member of the Consistory of Eötvös Loránd University (ELTE).